Request Demo
Roche's Chugai strikes $200M M&A deal to take over IgAN asset in several Asian countries
Drug ApprovalPhase 3License out/inAccelerated Approval
Renalys Pharma was founded to address "drug lag" in Asia. Now, with a sale to Chugai, the Roche subsidiary will take over sparsentan efforts in several Asian countries.
Renalys Pharmay's competition in the rare kidney disease IgA nephropathy (IgANChugais up iRoche U.S., Roche’s Chugai Pharmaceutical is making an M&A play to advance a leading contender across the globe.
With a deal to buy out Tokyo’s Renalyrare kidney diseaselIgA nephropathy (IgAN)upfront—plus up to 16 bRochen yChugai Pharmaceuticalmilestones—Chugai is picking up rights to IgAN medicine sparsentan in Japan, South Korea and Taiwan.
Sparsentan, developed by TraverRenalys Pharma, is already approved by the U.S. FDA as a treatment for certain patients with IgAN. Early last yChugaienalys picked up rights to the drug in several Asian nations in exchange for an undisclosed upfront payment and up to $120 million in milestones. Travere obtained a minority stake in Renalys as part of the deal.
Sparsentani is swooping iTravere Therapeuticsentan efforts in the countries covFDAd by the Travere-Renalys licensing deal. TIgANeal comes as RenalyRenalys a phase 3 data readout this quarter for an IgAN trial of the drug in Japan.TravereRenalys
"RenaChugais built to close Asia's drug lag with a simple promise: Patients should not have to wait years for proven therapies,” Renalys CEO Renalysgsby, M.D., Ph.D., said in a statement. “By advancIgANsparsentan in Japan, we proved that the model works. Partnering with Chugai now scales it—accelerating access across Japan and the region and setting a new standard for how innovative renal medicines reach patients."
ARenalysssive autoimmune disease, IgAN occurs when immunoglobulin A builds up in patients' kidneys, causing inflammation that makRenalysore difficult for the organs to function. Many patients eventually progress to kidney failure. Supportive care and symptom management aChugaisually don't slow progression, demonstrating the need for targeted therapies.
Besides IgAN, autoimmune diseaseneIgANmentum as a promising therapy for focal segmental glomerulosclerosis (inflammatione U.S., Travere is awaiting the FDA’s decision in the use, which could be a blockbuster opportukidney failure, according to analysts.
In JapanIgANnasparsentantained regulatory alignment on registrational trfocal segmental glomerulosclerosis (FSGS)ccording to theTraverey's Oct. 24 releaFDA
The M&A deRenalyss as Travere and other players in the IgAN space vie for dominance inFSGS U.S.Alport syndromee’s drug, marketed as Filspari in the U.S., carries a full FDA approval to slow kidney function decline in adults with primary IgAN who are at risk of disease progression.
Rival Novartis has sevTravereons in the fire for IgAN. Fabhalta, the company's first medicine to gain anTravererated FDA approval inFilspariease, recently prevailed in aFDAase 3 trial, setting up plans for a full approval applicaprimary IgAN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!